Background: Dental Anxiety (DA) may produce a vicious cycle where dental problems are not adequately serviced. Chronic non-compliance with prescribed dental care and maintenance is associated ultimately with poor dental health. Current pharmacologic treatments such as benzodiazepines for DA are associated with poor efficacy and significant side effects.The anxiolytic effects of the most studied cannabinoid, cannabidiol (CBD) in the Dual Dosing (AM/PM) Full Spectrum Protocol are detailed here (DDFSP). Materials and methods: Our recently developed PhytoDental Solutions Dental Anxiety Scale (PDSDAS) composed of eight self-reported psychic, somatic and sleep indicators was utilized for scoring a subject’s DA level for three Time Groups (TG): the night before (T0); immediately after (T1); and 24 hours (T2) after a dental procedure or visit. Results: In this series of subjects completing at least one post-dosing time point, the Dual Dosing AM/PM Full Spectrum CBD (DDFSCBD) Protocol significantly reduced both psychic (43% to 67%) and somatic (51%) dental anxiety. Additionally, 87% of study patients reported substantially improved sleep the night before their dental visit. Kruskai-Wallis one-way ANOVA analysis of the three Time Group data sets yielded significant 1-tail statistical differences (p-values< 0.05) with p-values of 0.020 and 0.041 substantiating the role of the DDFSP to modify DA. Further, validation of the PDSDAS as a scoring measure developed for DA was extended by paired t-test comparisons to multiple smaller Paired Data sets across these Time Groups yielding 1-tail p-values of 0.010, 0.050 and 0.024 respectively. Conclusion: Determination of significance by both ANOVA and paired t-tests of PDSDAS scoring strongly suggest the Dual-Dosing (AM/PM) Full Spectrum Protocol is an effective Dental Anxiety anxiolytic.
Dental Anxiety Management by Full Spectrum CBD Formulations: Dual Dosing (AM/PM) Protocol in A Real-World Setting